Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026

Pulnovo Medical, a Shanghai-based company developing therapies for pulmonary hypertension and heart failure, has raised $100 million in a strategic financing round led by Medtronic, which has also entered into a separate commercial agreement with the company exploring future commercialisation opportunities. Pulnovo’s flagship product is the Pulmonary Artery Denervation (PADN) System, a minimally invasive device […]

Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026 Read Post »

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach targeting the sympathetic nervous system’s role in pulmonary hypertension, reveal the findings of a metanalysis reviewing 14 studies, involving 372 patients. Pulmonary Artery Denervation improved several key hemodynamic parameters and clinical outcomes. The meta-analysis was published in the May 2025 edition of the International Journal

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition Read Post »

TRANSLATE »
Scroll to Top